Artemis Biosystems wins NIIMBL consortium grant for scalable lentiviral vector manufacturing

January 1, 2019

The National Institute for Innovative Manufacturing of Biopharmaceuticals  (NIIMBL) has awarded the consortium comprised of Artemis Biosystems, Johns Hopkins University, MassBiologics, Rensselaer  Polytechnic Institute, Repligen and  Unum Therapeutics a grant entitled "Improved Lentiviral Vector Biomanufacturing for Cell and Gene Therapy Applications”. The consortium will use VHU technology supplied by Artemis Biosystems to achieve its goal of developing a perfusion-based method of highly efficient, large  scale manufacturing of lentiviral vectors. See:

Bluebird Bio is evaluating VHU technology

February 20, 2018

Bluebird Bio (, a leading gene therapy company based in Cambridge (MA), is working with Artemis Biosystems to evaluate its VHU filtration technologies as part of its ongoing viral vector process development efforts.